Thermo Fisher Scientific Inc. TMO
Regular-session close
After hours · Nov 20, 6:41 PM ET
- YTD
- +15.55%
- 1 year
- +16.90%
5D -29.98 (-4.28%)
- Market cap
- 248.08B
- Revenue (ttm)
- 47.35B
- Profit margin
- 14.94%
- EPS (ttm)
- 18.96
- Shares out
- 370.52M
- P/E ratio
- 35.31
- Forward P/E
- 24.16
- Dividend
- 1.88 (0.27%)
- Ex-dividend date
- Dec 15, 2026
- YTD return
- +15.55%
- 1-year return
- +16.90%
- Volume
- 2.36M
- Avg volume
- 2.14M
- Open
- 689.72
- Previous close
- 688.75
- Day's range
- 667.95 – 692.00
- 52-week range
- 438.34 – 721.63
- Beta
- 0.84
- Analysts
- Strong Buy
- Price target
- 756.52 (+13.0%)
- Earnings date
- Feb 4, 2027
- 50-day average
- 677.30
Key statistics
- 200-day average
- 557.69
- Enterprise value
- 290.64B
- PEG ratio
- 2.01
- Price / sales
- 5.25
- Price / book
- 4.54
- Payout ratio
- 9.70%
- Revenue growth
- 9.10%
- Free cash flow
- 6.44B
- Total cash
- 6.06B
- Total debt
- 41.37B
- Return on equity
- 13.38%
- Short % of float
- 1.29%
Fundamental scorecard
14 of 25 checks passed on TMO’s reported financials
14of 25 checks passed
- Value 0 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 3 of 5
- Dividend 4 of 5
Statements to Sep 26, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 590.00
- Target (mean)
- 756.52
- Target (high)
- 830.00
- Strong buy3
- Buy20
- Hold3
- Sell0
- Strong sell1
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 7.12.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 26, 2026 | 7.12 | — | — | — |
| Oct 21, 2026 | Sep 26, 2026 | 6.40 | 6.68 | +0.28 | +4.37% |
| Jul 23, 2026 | Jun 27, 2026 | 5.72 | 6.03 | +0.31 | +5.42% |
| Apr 23, 2026 | Mar 28, 2026 | 5.25 | 5.44 | +0.19 | +3.62% |
| Jan 29, 2026 | Dec 31, 2025 | 6.45 | 6.57 | +0.12 | +1.86% |
| Oct 22, 2025 | Sep 27, 2025 | 5.50 | 5.79 | +0.29 | +5.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Argus Research | main | Buy | Buy |
| Oct 23, 2026 | Citigroup | main | Buy | Buy |
| Oct 22, 2026 | Barclays | main | Overweight | Overweight |
| Oct 22, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 22, 2026 | TD Cowen | main | Buy | Buy |
| Oct 22, 2026 | Stifel | main | Buy | Buy |
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- thermofisher.com
News
Thermo Fisher (TMO) Up 1.8% Since Last Earnings Report: Can It Continue?
Thermo Fisher Scientific Inc. (TMO) Presents at UBS 2026 CEO Call Series Transcript
Thermo Fisher Scientific Sees Faster 2027 Growth as Biotech Spending Recovers
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
If You Invested $100 In Thermo Fisher Scientific Stock 10 Years Ago, You Would Have This Much Today
Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production
Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings Thermo Fisher Scientific Announces $5B Buyback Plan
$100 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Your note
Sign in to keep a note on TMO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOXER MICHAEL A | General Counsel | Sale | Mar 9, 2025 | 10,815 |
| BRITT LISA P | Officer | Sale | Aug 18, 2026 | 14,784 |
| CASPER MARC N | Chief Executive Officer | Sale | Aug 23, 2026 | 140,225 |
| CHAI NELSON J | Director | Stock Award(Grant) | May 19, 2026 | 15,316 |
| LAGARDE MICHEL | Chief Operating Officer | Stock Award(Grant) | Feb 24, 2026 | 86,347 |
| LOWERY FREDERICK M. | Officer | Stock Award(Grant) | Feb 24, 2026 | 17,133 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.68% | 32,167,485 | 21.59B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 24,206,144 | 16.25B | Sep 29, 2026 |
| FMR, LLC | 5.98% | 22,173,792 | 14.88B | Sep 29, 2026 |
| State Street Corporation | 4.56% | 16,892,592 | 11.34B | Sep 29, 2026 |
| Morgan Stanley | 2.84% | 10,518,340 | 7.06B | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 2.82% | 10,437,681 | 7.01B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 11,797,800 | 7.92B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 9,628,713 | 6.46B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 4,926,507 | 3.31B | Sep 29, 2026 |
| Fidelity Contrafund | 1.33% | 4,919,704 | 3.30B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 4,805,216 | 3.23B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.23% | 4,572,555 | 3.07B | Sep 29, 2026 |
